MAGE-RING Protein Complexes Comprise a Family of E3 Ubiquitin Ligases

被引:383
作者
Doyle, Jennifer M. [4 ]
Gao, Jinlan [1 ,3 ]
Wang, Jiawei [1 ,2 ]
Yang, Maojun [1 ,2 ]
Potts, Patrick Ryan [4 ]
机构
[1] Tsinghua Univ, MOE Key Lab Bioinformat, Beijing 100084, Peoples R China
[2] Tsinghua Univ, Sch Life Sci, Struct Biol Ctr, Beijing 100084, Peoples R China
[3] Tsinghua Univ, PUMC, Natl Lab Med Mol Biol, Beijing 100084, Peoples R China
[4] Univ Texas SW Med Ctr Dallas, Dept Biochem, Dallas, TX 75390 USA
基金
中国国家自然科学基金;
关键词
HOMOLOGOUS RECOMBINATION; CANCER/TESTIS ANTIGENS; CANCER-IMMUNOTHERAPY; MDM2; INTERACTION; EMERGING ROLES; NECDIN GENE; CELL-LINES; MELANOMA; EXPRESSION; KAP1;
D O I
10.1016/j.molcel.2010.08.029
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The melanoma antigen (MAGE) family consists of more than 60 genes, many of which are cancer-testis antigens that are highly expressed in cancer and play a critical role in tumorigenesis. However, the biochemical and cellular functions of this enigmatic family of proteins have remained elusive. Here, we identify really interesting new gene (RING) domain proteins as binding partners for MAGE family proteins. Multiple MAGE family proteins bind E3 RING ubiquitin ligases with specificity. The crystal structure of one of these MAGE-RING complexes, MAGE-G1-NSE1, reveals structural insights into MAGE family proteins and their interaction with E3 RING ubiquitin ligases. Biochemical and cellular assays demonstrate that MAGE proteins enhance the ubiquitin ligase activity of RING domain proteins. For example, MAGE-C2-TRIM28 is shown to target p53 for degradation in a proteasome-dependent manner, consistent with its tumorigenic functions. These findings define a biochemical and cellular function for the MAGE protein family.
引用
收藏
页码:963 / 974
页数:12
相关论文
共 41 条
[1]   Trim24 targets endogenous p53 for degradation [J].
Allton, Kendra ;
Jain, Abhinav K. ;
Herz, Hans-Martin ;
Tsai, Wen-Wei ;
Jung, Sung Yun ;
Qin, Jun ;
Bergmann, Andreas ;
Johnson, Randy L. ;
Barton, Michelle Craig .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2009, 106 (28) :11612-11616
[2]   The MAGE proteins: Emerging roles in cell cycle progression, apoptosis, and neurogenetic disease [J].
Barker, PA ;
Salehi, A .
JOURNAL OF NEUROSCIENCE RESEARCH, 2002, 67 (06) :705-712
[3]   Tissue microarray evaluation of melanoma antigen E (MAGE) tumor-associated antigen expression - Potential indications for specific immunotherapy and prognostic relevance in squamous cell lung carcinoma [J].
Bolli, M ;
Kocher, T ;
Adamina, M ;
Guller, U ;
Dalquen, P ;
Haas, P ;
Mirlacher, M ;
Gambazzi, F ;
Harder, F ;
Heberer, M ;
Sauter, G ;
Spagnoli, GC .
ANNALS OF SURGERY, 2002, 236 (06) :785-793
[4]   RING domains: Master builders of molecular scaffolds? [J].
Borden, KLB .
JOURNAL OF MOLECULAR BIOLOGY, 2000, 295 (05) :1103-1112
[5]   EXPRESSION OF MAGE GENES IN PRIMARY AND METASTATIC CUTANEOUS MELANOMA [J].
BRASSEUR, F ;
RIMOLDI, D ;
LIENARD, D ;
LETHE, B ;
CARREL, S ;
ARIENTI, F ;
SUTER, L ;
VANWIJCK, R ;
BOURLOND, A ;
HUMBLET, Y ;
VACCA, A ;
CONESE, M ;
LAHAYE, T ;
DEGIOVANNI, G ;
DERAEMAECKER, R ;
BEAUDUIN, M ;
SASTRE, X ;
SALAMON, E ;
DRENO, B ;
JAGER, E ;
KNUTH, A ;
CHEVREAU, C ;
SUCIU, S ;
LACHAPELLE, JM ;
POUILLART, P ;
PARMIANI, G ;
LEJEUNE, F ;
CEROTTINI, JC ;
BOON, T ;
MARCHAND, M .
INTERNATIONAL JOURNAL OF CANCER, 1995, 63 (03) :375-380
[6]   GSK's antigen-specific cancer immunotherapy programme: Pilot results leading to Phase III clinical development [J].
Brichard, Vincent G. ;
Lejeune, Diane .
VACCINE, 2007, 25 :B61-B71
[7]  
Chomez P, 2001, CANCER RES, V61, P5544
[8]  
Cilensek ZM, 2002, CANCER BIOL THER, V1, P380
[9]  
De Smet C, 1999, MOL CELL BIOL, V19, P7327
[10]   INVOLVEMENT OF 2 ETS BINDING-SITES IN THE TRANSCRIPTIONAL ACTIVATION OF THE MAGE1 GENE [J].
DESMET, C ;
COURTOIS, SJ ;
FARAONI, I ;
LURQUIN, C ;
SZIKORA, JP ;
DEBACKER, O ;
BOON, T .
IMMUNOGENETICS, 1995, 42 (04) :282-290